The Antibody Society continuously collects data for approved antibody therapeutics and those in regulatory review in any country. A searchable table of this data is below. Products that were granted approvals but subsequently withdrawn from the market are included in the table. Biosimilar products are excluded.
Format, Fc modification and cell expression system data were compiled by Drs.Alicia Chenoweth and Silvia Crescioli, King’s College London, who also created the data table below.
The table below is an interactive table that can be filtered based on multiple conditions. Please use the filtering criteria above the table and type in the search boxes in the header of each column.
Scroll right to see all the columns.
Please cite our data as follows: The Antibody Society. Therapeutic monoclonal antibodies approved or in regulatory review. (date accessed); www.antibodysociety.org/antibody-therapeutics-product-data
Questions, comments, corrections? Please contact us at info@antibodysociety.org!
INNBrand NameTargetFormatSpecificitySequence sourceBackboneLight ChainConjugated / unconjugatedLinkerPayloadPayload Mechanism of ActionFc ModificationsReason for Fc ModificationsTherapeutic AreaIndication First Approved or ReviewedFirst EU approval yearFirst US approval yearFirst global approval (country, year) or country in reviewExpression system [fam-]trastuzumab deruxtecan, (fam-trastuzumab deruxtecan-nxki)EnhertuHER2Full-length antibodyMonospecificHumanizedIgG1kappaADCGlycine-Glycine-Phenylalanine-Glycine (GGFG; Cleable linker)DXdtopoisomerase I inhibitorNone-CancerHER2+ metastatic breast cancer20212019US, 2019Chinese hamster ovary (CHO) cells AbciximabReoproGPIIb/IIIaFabMonospecificChimeric mouse/humanFab (CH1 IgG1)kappaUnconjugatedNot applicable-Cardiovascular / hemostasisPrevention of blood clots in angioplasty1995*1994US, 1994Murine myeloma cells (Sp2/0) AdalimumabHumiraTNFFull-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-Immune-mediated disordersRheumatoid arthritis20032002US, 2002Chinese hamster ovary (CHO) cells AdebrelimabArebelimabPD-L1Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228P, F234A, L235AHinge stabilisation; abrogate effector functionCancerSmall cell lung cancerNANAChina, 2023To be confirmed Ado-trastuzumab emtansineKadcylaHER2Full-length antibodyMonospecificHumanizedIgG1kappaADCNon-cleable SMCC thioether linkerDM1tubulin polymerization inhibitorNone-CancerBreast cancer20132013US, 2013Chinese hamster ovary (CHO) cells AducanumabADUHELMAmyloid betaFull-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-Neurological disordersAlzheimer's diseaseMAA withdrawn2021US, 2021Chinese hamster ovary (CHO) cells AlemtuzumabLemtrada; MabCampath, Campath-1HCD52Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-CancerMultiple sclerosis; chronic myeloid leukemia#2013; 2001#2014; 2001#US, 2001Chinese hamster ovary (CHO) cells AlirocumabPraluentPCSK9Full-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-Metabolic disordersHigh cholesterol20152015US, 2015Chinese hamster ovary (CHO) cells AmivantamabRYBREVANTEGFR, cMETFull-length antibodyBispecificHumanIgG1kappaUnconjugatedLow-fucose; K409R; F405LImprove FcγRIIIa binding/Improve ADCC; Controlled Fab arm exchange for bispecific generationCancerNSCLC w/ EGFR exon 20 insertion mutations20212021US, 2021Chinese hamster ovary (CHO) cells, Low-fucose production cells Amubarvimab + RomlusevimabSARS-CoV-2Full-length antibodyMixture of 2 monospecific antibodiesHumanIgG1kappa and lambda2UnconjugatedM252Y/S254T/T256EHalf-life extensionInfectious diseasesSARS-CoV-2 infectionNANAChina, 2021#To be confirmed Anifrolumab, anifrolumab-fniaSaphneloIFNAR1Full-length antibodyMonospecificHumanIgG1kappaUnconjugatedL234F; L235E; P331SReduce Fc effector functionsImmune-mediated disordersSystemic lupus erythematosus20222021US, 2021Mouse myeloma cells (NS0) Ansuvimab-zyklEbangaEbola virus glycoproteinFull-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-Infectious diseasesEbola virus infectionNA2020US, 2020Chinese hamster ovary (CHO) cells AtezolizumabTecentriqPD-L1Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedAglycosylated (N297A)Aglycosylation, remove Fc effector functionsCancerBladder cancer20172016US, 2016Chinese hamster ovary (CHO) cells Atoltivimab, maftivimab, and odesivimab-ebgnInmazebEbola virusFull-length antibodies, mixture of 3Mixture of 3 monospecific antibodiesHumanIgG1kappaUnconjugatedNone-Infectious diseasesEbola virus infectionNA2020US, 2020Chinese hamster ovary (CHO) cells AvelumabBencioPD-L1Full-length antibodyMonospecificHumanIgG1lambdaUnconjugatedNone-CancerMerkel cell carcinoma20172017US, 2017Chinese hamster ovary (CHO) cells BasiliximabSimulectIL-2RFull-length antibodyMonospecificChimeric mouse/humanIgG1kappaUnconjugatedNone-Immune-mediated disordersPrevention of kidney transplant rejection19981998US, 1998Murine myeloma non-secreting 0 (NS0) cells BatoclimabFcRnFull-length antibodyMonospecificHumanIgG1lambdaUnconjugatedL234A, L235AReduce Fc effector functionsImmune-mediated disordersGeneralized myasthenia gris (gMG)NANARegulatory review in ChinaTo be confirmed Belantamab mafodotin (belantamab mafodotin-blmf)BLENREPBCMAFull-length antibodyMonospecificHumanizedIgG1kappaADCnoncleable maleimidocaproyl (mc) linkerMonomethyl Auristatin F (MMAF)tubulin polymerization inhibitorAfucosylatedImprove FcγRIIIa binding/Improve ADCCCancerMultiple myeloma20202020#US, 2020Chinese hamster ovary (CHO) cells, FUT8−/− CHO cells (Potelligent® Technology) BelimumabBenlystaBLySFull-length antibodyMonospecificHumanIgG1lambdaUnconjugatedNone-Immune-mediated disordersSystemic lupus erythematosus20112011US, 2011Murine myeloma non-secreting 0 (NS0) cells BenralizumabFasenraIL-5R αFull-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedAfucosylatedImprove FcγRIIIa binding/Improve ADCCImmune-mediated disordersAsthma20182017US, 2017Chinese hamster ovary (CHO) cells, FUT8−/− CHO cells (Potelligent® Technology) BevacizumabAvastinVEGF-AFull-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-CancerColorectal cancer20052004US, 2004Chinese hamster ovary (CHO) cells BezlotoxumabZinplaClostridium difficile enterotoxin BFull-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-Infectious diseasesPrevention of Clostridium difficile infection recurrence20172016US, 2016Chinese hamster ovary (CHO) cells Bimekizumab (bimekizumab-bkzx)BimzelxIL-17A and IL-17F (overlapping binding site)Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-Immune-mediated disordersPsoriasis20212023EU, 2021Chinese hamster ovary (CHO) cells BlinatumomabBlincytoCD19, CD3Tandem scFvBispecificMurineTandem scFvNAUnconjugatedNot applicable-CancerAcute lymphoblastic leukemia20152014US, 2014Chinese hamster ovary (CHO) cells Brentuximab vedotinAdcetrisCD30Full-length antibodyMonospecificChimeric mouse/humanIgG1kappaADCprotease cleable linker (Cathepsin cleable valine-citrulline)Monometyl auristan E (MMAE)tubulin polymerization inhibitorNone-CancerHodgkin lymphoma, systemic anaplastic large cell lymphoma20122011US, 2011Chinese hamster ovary (CHO) cells BrodalumabSiliq, LUMICEF, KyntheumIL-17RFull-length antibodyMonospecificHumanIgG2kappaUnconjugatedNone-Immune-mediated disordersPlaque psoriasis20172017Japan, 2016Chinese hamster ovary (CHO) cells Brolucizumab (brolucizumab-dbll)BeovuVEGF-AscFvMonospecificHumanizedscFvkappaUnconjugatedNot applicable-OphthalmologyNeovascular age-related macular degeneration20202019US, 2019E. coli BL21(DE3) bacteria Burosumab (burosumab-twza)CrysvitaFGF23Full-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-Genetic DiseasesX-linked hypophosphatemia20182018EU, 2018Chinese hamster ovary (CHO) cells Cadonilimab开坦尼®PD-1, CTLA4Full-length antibodyBispecificHumanizedIgG1kappaUnconjugatedL234A/L235A/G237AReduce Fc effector functionCancerCervical cancerNANAChina, 2022To be confirmed CamrelizumabAiRuiKaPD-1Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge stabilisationCancerHodgkin's lymphomaNAIn reviewChina, 2019To be confirmed CanakinumabIlarisIL-1βFull-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-Genetic DiseasesMuckle-Wells syndrome20092009US, 2009Murine myeloma cells (Sp2/0) Caplacizumab (caplacizumab-yhdp)Cablivivon Willebrand factorVHH (bivalent)MonospecificHumanizedVHH (bivalent)NAUnconjugatedNot applicable-Immune-mediated disordersAcquired thrombotic thrombocytopenic purpura20182019EU, 2018E. coli bacteria Casirivimab + imdevimabREGEN-COV, RonapreveSARS-CoV-2Full-length antibodies, mixture of 2Mixture of 2 monospecific antibodiesHumanIgG1kappa and lambdaUnconjugatedNone-Infectious diseasesCOVID-192021EUA#Japan, 2021Chinese hamster ovary (CHO) cells CatumaxomabKorjuny, RemovabEPCAM, CD3Full-length antibodyBispecificHybrid Rat/MousemIgG2a/k and rIgG2b/λ Hybridkappa/lambdaUnconjugatedNone-CancerMalignant ascites2025; 2009#NAEU, 2009Rat-mouse hybrid-hybridoma cell line Cemiplimab (cemiplimab-rwlc)LibtayoPD-1Full-length antibodyMonospecificHumanIgG4kappaUnconjugatedS228PHinge stabilisingCancerCutaneous squamous cell carcinoma20192018US, 2018Chinese hamster ovary (CHO) cells Certolizumab pegolCimziaTNFPEGylated FabMonospecificHumanizedFab (CH1 IgG1)kappaPEGylatedPEGextend half lifeNot applicable-Immune-mediated disordersCrohn disease20092008US, 2008E. coli bacteria CetuximabErbituxEGFRFull-length antibodyMonospecificChimeric mouse/humanIgG1kappaUnconjugatedNone-CancerColorectal cancer20042004Switzerland, 2003Murine myeloma cells (Sp2/0) Cetuximab saratolacanAkalux® IV InfusionEGFRFull-length antibodyMonospecificChimericIgG1kappaPhotoimmunotherapyIRDye® 700DXNone-CancerHead and neck cancerNANAJapan, 2020To be confirmed ConcizumabAlhemo™Tissue factor pathway inhibitorFull-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge-stabilizationCardiovascular / hemostasisHemophilia A or B20242024Canada, 2023Chinese hamster ovary (CHO) cells Cosibelimab, cosibelimab-ipdlUnloxcytPD-L1Full-length antibodyMonospecificHumanIgG1lambdaUnconjugatedNoneCancerSquamous cell carcinomaNA2024US, 2024Chinese hamster ovary (CHO) cells Crizanlizumab (crizanlizumab-tmca)AdakveoCD62 (aka P-selectin)Full-length antibodyMonospecificHumanizedIgG2kappaUnconjugatedNone-Cardiovascular / hemostasisSickle cell disease2020#2019US, 2019Chinese hamster ovary (CHO) cells Crovalimab派圣凯®, PiaSkyComplement C5Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedL235R, G236R, S239K, A327G, A330S, P331S; M428L, N434A, Q438R, S440EImpair Fc binding/effector functions; increase FcnR binding without increasing RF bindingCardiovascular / hemostasisAtypical hemolytic uremic syndrome20242024China, 2024Chinese hamster ovary (CHO) cells DaclizumabZinbryta; ZenapaxCD25Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-Immune-mediated disordersMultiple sclerosis#; prevention of kidney transplant rejection#2016#; 1999#2016#; 1997#US, 1997Murine myeloma non-secreting 0 (NS0) cells DaratumumabDarzalexCD38Full-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-CancerMultiple myeloma20162015US, 2015Chinese hamster ovary (CHO) cells DenosumabProliaRANK-LFull-length antibodyMonospecificHumanIgG2kappaUnconjugatedNone-Musculoskeletal DisordersBone Loss20102010EU, 2010Chinese hamster ovary (CHO) cells DinutuximabUnituxinGD2Full-length antibodyMonospecificChimeric mouse/humanIgG1kappaUnconjugatedNone-CancerNeuroblastoma2017; 2015#2015US, 2015Murine myeloma cells (Sp2/0) Disitamab vedotinAidixiHER2Full-length antibodyMonospecificHumanizedIgG1kappaADCcleable maleimidocaproyl-valyl-citrullinyl-p-amiobenzyloxycarbonyl (mc-val-cit-PABC) type linkerMMAENone-CancerGastric cancerNANAChina, 2021To be confirmed DivozilimabIvliziCD20Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNoneImmune-mediated disordersMultiple sclerosisNANARussia, 2023To be confirmed Docarimab and MiromimabTwinrabRabies virusFull-length antibody, mixture of 2Mixture of 2 monospecific antibodiesMurinemIgG2b and mIgG1kappaUnconjugatedNone-Infectious diseasesRabies exposureNANAIndia, 2019To be confirmed DonanemabKisunlaAmyloid beta, N3pG (N-terminal truncated)Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-Neurological disordersAlzheimer's diseaseEU review2024US, 2024Chinese hamster ovary (CHO) cells DostarlimabJemerliPD-1Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge stabilisingCancerEndometrial cancer20212021EU, 2021Chinese hamster ovary (CHO) cells DupilumabDupixentIL-4RαFull-length antibodyMonospecificHumanIgG4kappaUnconjugatedS228PHinge stabilisingImmune-mediated disordersAtopic dermatitis20172017US, 2017Chinese hamster ovary (CHO) cells DurvalumabIMFINZIPD-L1Full-length antibodyMonospecificHumanIgG1kappaUnconjugatedL234F; L235E; P331SReduce Fc effector functionsCancerBladder cancer20182017US, 2017Chinese hamster ovary (CHO) cells Ebronucimab伊喜宁PCSK9Full-length antibodyMonospecificHumanIgG1lambda2UnconjugatedNoneMetabolic disordersPrimary hypercholesterolemia and mixed hyperlipidemia, and heterozygous familial hypercholesterolemiaNANAChina, 2024To be confirmed EculizumabSolirisComplement C5Full-length antibodyMonospecificHumanizedIgG2(CH1-hinge)/IgG4(CH2-CH3)kappaUnconjugatedNone-Cardiovascular / hemostasisParoxysmal nocturnal hemoglobinuria20072007US, 2007Murine myeloma non-secreting 0 (NS0) cells EdrecolomabPanorexEpCAMFull-length antibodyMonospecificMurinemIgG2akappaUnconjugatedNone-CancerColon cancer1995*#NAGermany, 1995To be confirmed EfalizumabRaptivaCD11aFull-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-Immune-mediated disordersPsoriasis2004#2003#US, 2003Chinese hamster ovary (CHO) cells ElotuzumabEmplicitiSLAMF7Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-CancerMultiple myeloma20162015US, 2015Murine myeloma non-secreting 0 (NS0) cells ElranatamabElrexfioBCMA, CD3Full-length antibodyBispecificHumanizedIgG2kappaUnconjugated: IgG1RRR: 221R, 228R, K409R or IgG2deltaA-RRRR: 223R, 225R, 228R, K409R; Target antibody: IgG1EEE: 221E, 228E, L368E or IgG2deltaA-EEEE: 223E, 225E, 228E, L368E, Exchange with 1-2 mM GSH).Strop Fab-arm exchange methodCancerMultiple myeloma20232023US, 2023Chinese hamster ovary (CHO) cells Emapalumab (emapalumab-lzsg)GamifantIFNgFull-length antibodyMonospecificHumanIgG1lambdaUnconjugatedNone-CancerPrimary hemophagocytic lymphohistiocytosisNA2018US, 2018Chinese hamster ovary (CHO) cells EmicizumabHemlibraFactor IXa, Factor XFull-length antibodyBispecificHumanizedIgG4kappaUnconjugatedS228P; K196Q; F296Y; E356K; K439E; L445P; G446 > del; K447 > delHinge stabilising, asymmetric electrostatic steering mutations for bispecific creationCardiovascular / hemostasisHemophilia A20182017US, 2017Chinese hamster ovary (CHO) cells Enfortumab vedotin (enfortumab vedotin-ejfv)PadcevNectin-4Full-length antibodyMonospecificHumanIgG1kappaADCProtease-cleable Valine-Citrulline (mc-val-cit PABC linkerMonomethyl Auristatin E (MMAE)tubulin polymerization inhibitorNone-CancerUrothelial cancer20222019US, 2019Chinese hamster ovary (CHO) cells EnlonstobartEnshuxing, 恩舒幸®PD-1Full-length antibodyMonospecificHumanIgG4kappaUnconjugatedS228PHinge stabilisingCancerCervical cancerNANAChina, 2024Chinese hamster ovary (CHO) cells EnvafolimabENWEIDAPD-L1VHH-FcMonospecificHumanized single doman; human FcVHH-Fc (Fc IgG1)UnconjugatedC220S/D265A/P331SReduce Fc effector function (ADCC/ADCP)CancerMicrosatellite instability-high or deficient MisMatch Repair advanced solid tumorsNANAChina, 2021To be confirmed EpcoritamabTEPKINLY, EPKINLY™CD20, CD3Full-length antibodyBispecificHumanizedIgG1; Hetero Hlambda/kappaUnconjugatedHetero HH, HL exchanged: L234F x K409R (bispecific assembly) both chains L234F, L235E, D265A (Fc silencing)Chain pairing, Reduce Fc effector functionCancerDiffuse large B-cell lymphoma20232023US, 2023Chinese hamster ovary (CHO) cells Eptinezumab (eptinezumab-jjmr)VYEPTICGRPFull-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedAglycosylated (N297A)Aglycosylation, remove Fc effector functionsNeurological disordersMigraine prevention20222020US, 2020Pichia pastoris yeast cells Erenumab (erenumab-aooe)AimovigCGRP receptorFull-length antibodyMonospecificHumanIgG2lambdaUnconjugatedNone-Neurological disordersMigraine prevention20182018US, 2018Chinese hamster ovary (CHO) cells EvinacumabEvkeezaAngiopoietin-like 3Full-length antibodyMonospecificHumanIgG4kappaUnconjugatedS228PHinge stabilisingMetabolic disordersHomozygous familial hypercholesterolemia20212021US, 2021Chinese hamster ovary (CHO) cells EvolocumabRepathaPCSK9Full-length antibodyMonospecificHumanIgG2lambdaUnconjugatedNone-Metabolic disordersHigh cholesterol20152015EU, 2015Chinese hamster ovary (CHO) cells Faricimab, faricimab-svoaVabysmoVEGF-A, Ang-2Full-length antibodyBispecificHumanized/humanIgG1kappa/lambdaUnconjugatedL234A; L235A; P329G; I253A; H310A; H435A; S354C + T366W (in hey chain A); Y349C + T366S + L368A + Y407V (in hey chain B)Reduce Fc effector functions; Reduce half-life; CrossMab "knob-in-hole" mutations for bispecific generationOphthalmologyNeovascular age-related macular degeneration, diabetic macular edema20222022US, 2022Chinese hamster ovary (CHO) cells Fremanezumab (fremanezumab-vfrm)AjovyCGRPFull-length antibodyMonospecificHumanizedIgG2ΔakappaUnconjugatedA330S; P331SReduce Fc effector functionsNeurological disordersMigraine prevention20192018US, 2018Chinese hamster ovary (CHO) cells Galcanezumab (galcanezumab-gnlm)EmgalityCGRPFull-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228P; F234A; L235ARemove Fc effector functionsNeurological disordersMigraine prevention20182018US, 2018Chinese hamster ovary (CHO) cells Gemtuzumab ozogamicinMylotargCD33Full-length antibodyMonospecificHumanizedIgG4kappaADCAcid-labile hydrozone linkerCalicheamicinDNA-binding and double breaks inductionS228PHinge stabilisingCancerAcute myeloid leukemia20182017; 2000#US, 2000Murine myeloma non-secreting 0 (NS0) cells GlofitamabCOLUMVI®CD20, CD3eFab-Fc x Fab-Fab-FcBispecificHumanizedIgG1; CrossMab; Fab-Fc(G1) x Fab-Fab-Fclambda/kappaUnconjugatedHetero HH: S354C-T366W x Y349C-T366S-L368A-Y407V (KiH and extra cysteines); HL-pairing: CrossMab; both chains: L234A, L235A, P329G (Fc-silencing)Chain pairing, Reduce Fc effector functionCancerDiffuse large B-cell lymphoma20232023Canada, 2023Chinese hamster ovary (CHO) cells GolimumabSimponiTNFFull-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-Immune-mediated disordersRheumatoid and psoriatic arthritis, ankylosing spondylitis20092009US, 2009Murine myeloma cells (Sp2/0) GuselkumabTREMFYAIL-23 p19Full-length antibodyMonospecificHumanIgG1lambdaUnconjugatedNone-Immune-mediated disordersPlaque psoriasis20172017US, 2017Chinese hamster ovary (CHO) cells Ibalizumab (ibalizumab-uiyk)TrogarzoCD4Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedNone-Infectious diseasesHIV infection20192018US, 2018Murine myeloma non-secreting 0 (NS0) cells Ibritumomab tiuxetanZevalinCD20Full-length antibodyMonospecificMurinemIgG1kappaRICchalating agent MX-DTPAYttrium-90Y-90 produces beta emissionsNone-CancerNon-Hodgkin lymphoma20042002US, 2002Chinese hamster ovary (CHO) cells IdarucizumabPraxbindDabigatranFabMonospecificHumanizedFab (CH1 IgG1)kappaUnconjugatedNot applicable-Cardiovascular / hemostasisReversal of dabigatran-induced anticoagulation20152015US, 2015Chinese hamster ovary (CHO) cells Inebilizumab (inebilizumab-cdon)UpliznaCD19Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedAfucosylatedImprove FcγRIIIa binding/Improve ADCCImmune-mediated disordersNeuromyelitis optica spectrum disorders20222020US, 2020Chinese hamster ovary (CHO) cells, FUT8−/− CHO cells (Potelligent® Technology) InfliximabRemicadeTNFFull-length antibodyMonospecificChimeric mouse/humanIgG1kappaUnconjugatedNone-Immune-mediated disordersCrohn disease19991998US, 1998Murine myeloma cells (Sp2/0) Inotuzumab ozogamicinBESPONSACD22Full-length antibodyMonospecificHumanizedIgG4kappaADCAcid-labile hydrozone linkerCalicheamicinDNA-binding and double breaks inductionS228PHinge stabilisingCancerAcute lymphoblastic leukemia20172017US, 2017Chinese hamster ovary (CHO) cells IpilimumabYervoyCTLA-4Full-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-CancerMetastatic melanoma20112011US, 2011Chinese hamster ovary (CHO) cells Isatuximab (isatuximab-irfc)SarclisaCD38Full-length antibodyMonospecificChimeric mouse/humanIgG1kappaUnconjugatedNone-CancerMultiple myeloma20202020US, 2020Chinese hamster ovary (CHO) cells ItolizumabAlzumabCD6Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-Immune-mediated disordersPsoriasisNANAIndia, 2013To be confirmed IxekizumabTaltzIL-17AFull-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge stabilisingImmune-mediated disordersPsoriasis20162016US, 2016Chinese hamster ovary (CHO) cells Lanadelumab (lanadelumab-flyo)TakhzyroPlasma kallikrelinFull-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-Genetic DiseasesHereditary angioedema attacks20182018US, 2018Chinese hamster ovary (CHO) cells LebrikizumabEBGLYSSIL-13Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge-stabilizationImmune-mediated disordersAtopic dermatitis20232024EU, 2023Chinese hamster ovary (CHO) cells LecanemabLeqembiAmyloid beta protofibrilsFull-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-Neurological disordersAlzheimer's diseasePos. opinion after review2023US, 2023Chinese hamster ovary (CHO) cells LevilimabIlsiraIL-6RFull-length antibodyMonospecificHumanIgG1kappaUnconjugatedE233P/L234V/L235A and M252Y/S254T/T256EReduce Fc effector function and extend half-lifeImmune-mediated disordersInflammation due to COVID-19 infectionNANARussia, 2020To be confirmed Loncastuximab tesirineZynlontaCD19Full-length antibodyMonospecificHumanizedIgG1kappaADCProtease-cleable Valine-Citrulline linkerpyrrolobenzodiazepines (PBD) dimer SG3199DNA minor-groove bindingNone-CancerDiffuse large B-cell lymphoma20222021US, 2021Chinese hamster ovary (CHO) cells Margetuximab-cmkbMARGENZAHER2Full-length antibodyMonospecificChimeric mouse/humanIgG1kappaUnconjugatedF243L; R292P; Y300L; V305I; P396LImprove FcγRIIIa binding/Improve ADCC and decrease affinity for human inhibitory FcγRIIB (CD32B)CancerHER2+ metastatic breast cancerNA2020US, 2020Chinese hamster ovary (CHO) cells MepolizumabNucalaIL-5Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-Immune-mediated disordersSevere eosinophilic asthma20152015US, 2015Chinese hamster ovary (CHO) cells MirikizumabOmvohIL-23p19Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228P; F234A, L235AHinge stabilisation; Reduce Fc effector functionImmune-mediated disordersUlcerative colitis20232023Japan, 2023Chinese hamster ovary (CHO) cells Mirvetuximab sortansineELAHEREFR𝛂Full-length antibodyMonospecificHumanizedIgG1kappaADCcleable sulfo-SPDB linkerDM4Tubulin polymerization inhibitorNone-CancerOvarian cancer20242022US, 2022Chinese hamster ovary (CHO) cells Mogamulizumab (mogamulizumab-kpkc)PoteligeoCCR4Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedAfucosylatedImprove FcγRIIIa binding/Improve ADCCCancerMycosis fungoides or Sézary syndrome20182018Japan, 2012Chinese hamster ovary (CHO) cells, FUT8−/− CHO cells (Potelligent® Technology) MosunetuzumabLunsumioCD20, CD3Full-length antibodyBispecificHumanizedIgG1; Hetero H, HL assemblykappaUnconjugatedHetero HH: T366W x T366S-L368A-Y407V (KiH); N297G (Fc-aglycosylated)KiH; aglycosylation, remove Fc effector functionsCancerFollicular lymphoma20222022EU, 2022Chinese hamster ovary (CHO) cells Moxetumomab pasudotox (moxetumomab pasudotox-tdfk)LumoxitiCD22dsFv immunotoxinMonospecificMurinedsFv fused with PE38 exotoxinImmunoconjugatePE38Not applicable-CancerHairy cell leukemia2021#2018#US, 2018E. coli bacteria Muromonab-CD3Orthoclone Okt3CD3Full-length antibodyMonospecificMurinemIgG2akappaUnconjugatedNone-Immune-mediated disordersReversal of kidney transplant rejection1986*1986#US, 1986Murine hybridoma NarlumosbartJinlitai, 津立泰RANK-LFull-length antibodyMonospecificHumanIgG4kappaUnconjugatedS228PHinge stabilisationMusculoskeletal DisordersGiant cell tumor of boneNANAChina, 2023Chinese hamster ovary (CHO) cells, cell line CHO-S, glycoform alfa Narsoplimab(Pending)MASP-2Full-length antibodyMonospecificHumanIgG4lambdaUnconjugatedS228PHinge stabilisingCardiovascular / hemostasisHematopoietic stem cell transplant-associated thrombotic microangiopathiesNAIn reviewTo be confirmed NatalizumabTysabria4 integrinFull-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedNone-Immune-mediated disordersMultiple sclerosis20062004US, 2004Murine myeloma non-secreting 0 (NS0) cells Naxitamab-gqgkDANYELZAGD2Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-CancerHigh-risk neuroblastoma and refractory osteomedullary diseaseNA2020US, 2020Chinese hamster ovary (CHO) cells NebacumabCentoxinEndotoxinFull-length antibodyMonospecificHumanIgMkappaUnconjugatedNone-Infectious diseasesGram-negative sepsis1991*#NANetherlands, England, France, Germany, 1991Heteromyeloma cell line A6(H4C5) NecitumumabPortrazzaEGFRFull-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-CancerNon-small cell lung cancer20152015US, 2015Murine myeloma non-secreting 0 (NS0) cells Nemolizumab (nemolizumab-ilto)Mitchga, NemluvioIL-31R𝛂Full-length antibodyMonospecificHumanizedIgG2kappaUnconjugatedC222S and H268QStructure stability, possibly reduce Fc effector functionImmune-mediated disordersPruritus with atopic dermatitis20252024Japan, 2022Chinese hamster ovary (CHO) cells NetakimabEfleiraIL-17Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedM252Y/S254T/T256EHalf-life extensionImmune-mediated disordersPlaque psoriasisNANARussia, 2019To be confirmed NimotuzumabTheraCIM, BIOMAB-EGFREGFRFull-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-CancerHead and neck cancerNANACuba, 2002To be confirmed NirsevimabBeyfortusRSVFull-length antibodyMonospecificHumanIgG1kappaUnconjugatedM252Y, S254T, T256EExtends half-lifeInfectious diseasesPrevention of respiratory syncytial virus infection20222023EU, 2022Chinese hamster ovary (CHO) cells NivolumabOpdivoPD-1Full-length antibodyMonospecificHumanIgG4kappaUnconjugatedS228PHinge stabilisingCancerMelanoma, non-small cell lung cancer20152014US, 2014Chinese hamster ovary (CHO) cells No INN; CipterbinCipterbinHER2Full-length antibodyMonospecificHumanizedIgG1To be confirmedUnconjugatedEnhanced ADCC/ADCP (exact mutations not found)CancerHER2-positive metastatic breast cancerNANAChina, 2020To be confirmed No INN; RabiShieldRabiShieldRabies virus G glycoproteinFull-length antibodyMonospecificHumanIgG1To be confirmedUnconjugatedInfectious diseasesRabies exposureNANAIndia, 2016To be confirmed ObiltoxaximabAnthimB. anthrasis PAFull-length antibodyMonospecificChimeric mouse/humanIgG1kappaUnconjugatedNone-Infectious diseasesPrevention of inhalational anthrax20202016US, 2016Murine GS-NS0 myeloma cells ObinutuzumabGazyva, GazyvaroCD20Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedLow-fucoseImprove FcγRIIIa binding/Improve ADCCCancerChronic lymphocytic leukemia20142013US, 2013Chinese hamster ovary (CHO) cells, Coexpression with GnT III and α-ManII in CHO cells (GlycoMAb Technology) OcrelizumabOCREVUSCD20Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-Immune-mediated disordersMultiple sclerosis20182017US, 2017Chinese hamster ovary (CHO) cells OfatumumabArzerraCD20Full-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-CancerChronic lymphocytic leukemia2010#2009US, 2009Murine myeloma non-secreting 0 (NS0) cells OlaratumabLartruvoPDGFRαFull-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-CancerSoft tissue sarcoma2016#2016US, 2016Murine myeloma non-secreting 0 (NS0) cells OlokizumabARTLEGIAIL-6Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge stabilisationImmune-mediated disordersRheumatoid arthritisNANARussia, 2020To be confirmed OmalizumabXolairIgEFull-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-Immune-mediated disordersAsthma20052003US, 2003Chinese hamster ovary (CHO) cells Ongericimab君适达®PCSK9Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge stabilisationMetabolic disordersHypercholesterolemiaNANAChina, 2024To be confirmed Ormutivimab(Pending)Rabies virus surface glycoprotein 4Full-length antibodyMonospecificHumanIgG1lambda2UnconjugatedNone-Infectious diseasesPost-exposure prophylaxis of rabiesNANAChina, 2022Chinese hamster ovary (CHO)-K1 cells OzoralizumabNanozoraⓇTNF, albuminVHH (trivalent)BispecificHumanizedVH-VH'-VHUnconjugatedNone-Immune-mediated disordersRheumatoid arthritisNANAJapan, 2022To be confirmed Pabinafusp alfaIZCARGOTransferrin receptorFull-length antibodyMonospecificHumanizedIgG1kappaImmunoconjugateIduronate-2-sulfataseNone-Metabolic disordersMucopolysaccharidosis type IINANAJapan, 2021To be confirmed PalivizumabSynagisRSVFull-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-Infectious diseasesPrevention of respiratory syncytial virus infection19991998US, 1998Murine myeloma non-secreting 0 (NS0) cells PanitumumabVectibixEGFRFull-length antibodyMonospecificHumanIgG2kappaUnconjugatedNone-CancerColorectal cancer20072006US, 2006Chinese hamster ovary (CHO) cells PembrolizumabKeytrudaPD-1Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge stabilisingCancerMelanoma20152014US, 2014Chinese hamster ovary (CHO) cells PenpulimabANNIKOPD-1Full-length antibodyMonospecificHumanizedIgG1To be confirmedUnconjugatedL234A L235A G237AReduce Fc effector functionsCancerMetastatic nasopharyngeal carcinomaNAIn reviewChina, 2021To be confirmed PertuzumabPerjetaHER2Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-CancerBreast Cancer20132012US, 2012Chinese hamster ovary (CHO) cells Polatuzumab vedotin (polatuzumab vedotin-piiq)PolivyCD79bFull-length antibodyMonospecificHumanizedIgG1kappaADCProtease-cleable Valine-Citrulline (mc-val-cit PABC linkerMonomethyl Auristatin E (MMAE)tubulin polimerization inhibitorNone-CancerDiffuse large B-cell lymphoma20202019US, 2019Chinese hamster ovary (CHO) cells PozelimabVEOPOZComplement C5Full-length antibodyMonospecificHumanIgG4kappaUnconjugatedS228PHinge stabilisationCardiovascular / hemostasisCHAPLE diseaseNA2023US, 2023Chinese hamster ovary (CHO) cells ProlgolimabFortecaPD-1Full-length antibodyMonospecificHumanIgG1V-lambda C-kappaUnconjugatedL234A/L235AReduce Fc effector functionCancerMelanomaNANARussia, 2020To be confirmed PucotenlimabPuyouhengPD-1Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228P, S254T, V308P, N434AHinge stabilsation, half-life extensionCancerMetastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors,NANAChina, 2022To be confirmed RacotumomabVaxira®GM3Full-length antibodyMonospecificMurinemIgG1kappaUnconjugated--CancerNon-small cell lung cancerNANACuba, 2013To be confirmed RamucirumabCyramzaVEGFR2Full-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-CancerGastric cancer20142014US, 2014Murine myeloma non-secreting 0 (NS0) cells RanibizumabLucentisVEGF-AFabMonospecificHumanizedFab (CH1 IgG1)kappaUnconjugatedNot applicable-OphthalmologyMacular degeneration20072006US, 2006E. coli bacteria Rulizumab (rulizumab-cwvz)UltomirisComplement C5Full-length antibodyMonospecificHumanizedIgG2(CH1-hinge)/IgG4(CH2-CH3)kappaUnconjugatedM428L; N434SIncrease half-lifeCardiovascular / hemostasisParoxysmal nocturnal hemoglobinuria20192018US, 2018Chinese hamster ovary (CHO) cells Raxibacumab(Pending)B. anthrasis PAFull-length antibodyMonospecificHumanIgG1lambdaUnconjugatedNone-Infectious diseasesAnthrax infectionNA2012US, 2012Murine myeloma non-secreting 0 (NS0) cells RegdanvimabRegkironaSARS-CoV-2Full-length antibodyMonospecificHumanIgG1lambdaUnconjugatedNone-Infectious diseasesCOVID-192021NARepublic of Korea, 2021Chinese hamster ovary (CHO)-K1 cells RelatlimabOpdualag (relatlimab + nivolumab combo)LAG-3Full-length antibodyMonospecificHumanIgG4kappaUnconjugatedS228PHinge stabilisingCancerMelanoma20222022US, 2022Chinese hamster ovary (CHO) cells ReslizumabCinqaero, CinqairIL-5Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedNone-Immune-mediated disordersAsthma20162016US, 2016Murine myeloma non-secreting 0 (NS0) cells RetifanlimabZynyzPD-1Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge stabilisingCancerMerkel cell carcinoma20242023US, 2023Chinese hamster ovary (CHO) cells RipertamabAnpingxiCD20Full-length antibodyMonospecificChimeric mouse/humanIgG1kappaUnconjugatedNone-CancerNon-Hodgkin's lymphomaNANAChina, 2022To be confirmed Risankizumab (risankizumab-rzaa)SkyriziIL-23 p19Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedL234A; L235AReduce Fc effector functionsImmune-mediated disordersPlaque psoriasis20192019Japan, 2019Chinese hamster ovary (CHO) cells RituximabMabThera, RituxanCD20Full-length antibodyMonospecificChimeric mouse/humanIgG1kappaUnconjugatedNone-CancerNon-Hodgkin lymphoma19981997US, 1997Chinese hamster ovary (CHO) cells Romosozumab (romosozumab-aqqg)EvenitySclerostinFull-length antibodyMonospecificHumanizedIgG2kappaUnconjugatedNone-Musculoskeletal DisordersOsteoporosis in postmenopausal women at increased risk of fracture20192019Japan, 2019Chinese hamster ovary (CHO) cells RozanolixizumabRYSTIGGO®FcRnFull-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge-stabilizationImmune-mediated disordersGeneralized myasthenia gris20242023US, 2023Chinese hamster ovary (CHO) cells, DG44 Sacituzumab govitecan (sacituzumab govitecan-hziy)TRODELVYTROP-2Full-length antibodyMonospecificHumanizedIgG1kappaADCpH-sensitive cleable linkerSN38topoisomerase I inhibitorNone-CancerTriple-neg. breast cancer20212020US, 2020Murine myeloma cells SarilumabKevzaraIL-6RFull-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-Immune-mediated disordersRheumatoid arthritis20172017Canada, 2017Chinese hamster ovary (CHO) cells Satralizumab (satralizumab-mwge)EnspryngIL-6RFull-length antibodyMonospecificHumanizedIgG2kappaUnconjugatedNone-Immune-mediated disordersNeuromyelitis optica spectrum disorder20212020Canada, 2020Chinese hamster ovary (CHO) cells SecukinumabCosentyxIL-17AFull-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-Immune-mediated disordersPsoriasis20152015Japan, 2014Chinese hamster ovary (CHO) cells SerplulimabHetronifly, HANSIZHUANGPD-1Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge stabilisationCancerMicrosatellite instability-high solid tumors2025NAChina, 2022To be confirmed SiltuximabSylvantIL-6Full-length antibodyMonospecificChimeric mouse/humanIgG1kappaUnconjugatedNone-Immune-mediated disordersCastleman disease20142014US, 2014Chinese hamster ovary (CHO) cells SintilimabTyvytPD-1Full-length antibodyMonospecificHumanIgG4kappaUnconjugatedS228PHinge stabilisingCancerNon-small cell lung cancerNANAChina, 2018To be confirmed SocazolimabShan KeyuPD-L1Full-length antibodyMonospecificHumanIgG1lambda2UnconjugatedNone-CancerCervical cancerNANAChina, 2023To be confirmed SotrovimabXevudySARS-CoV-2Full-length antibodyMonospecificHumanIgG1kappaUnconjugatedM428L /N434SExtends half-lifeInfectious diseasesCOVID-192021NAAustralia, 2021Chinese hamster ovary (CHO) cells SpesolimabSPEVIGO®IL-36RFull-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedL234A/L235AReduce Fc effector functionsImmune-mediated disordersGeneralized pustular psoriasis20222022US, 2022Chinese hamster ovary (CHO) cells SugemalimabCejemly®PD-L1Full-length antibodyMonospecificHumanIgG4lambdaUnconjugatedS228PHinge stabilisationCancerNon-small cell lung cancer2024NAChina, 2021Chinese hamster ovary (CHO) cells Sutimlimab (sutimlimab-jome)EnjaymoComplement C1sFull-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228P; L235EHinge stabilising; remove Fc effector functionsImmune-mediated disordersCold agglutinin disease20222022US, 2022Chinese hamster ovary (CHO) cells Tafasitamab (tafasitamab-cxix)Monjuvi, MinjuviCD19Full-length antibodyMonospecificHumanizedIgG1/2 hybridkappaUnconjugatedS239D; I332EImprove FcγRIIIa binding/Improve ADCCCancerDiffuse large B-cell lymphoma20212020US, 2020Chinese hamster ovary (CHO) cells TafolecimabSINTBILOPCSK9Full-length antibodyMonospecificHumanIgG2kappaUnconjugatedNone-Metabolic disordersPrimary hypercholesterolemia (including heterozygous familial hypercholesterolemia and non-familial hypercholesterolemia) and mixed dyslipidemiaNANAChina, 2023To be confirmed Tagitanlimab科泰莱®PD-L1Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedL234A L235A G237AReduce Fc effector functionCancerNasopharyngeal carcinoma, solid tumorNANAChina, 2024To be confirmed Talquetamab (talquetamab-tgvs)TalveyGPCR5D, CD3Full-length antibodyBispecificHumanizedIgG4lambda/kappaUnconjugatedHetero HH: F405L-R409K x WT; both chains: S228P, F234A-L235AHinge-stabilization (S228P), Reduce Fc effector function (F234A-L235A)CancerMultiple myeloma20232023US, 2023Chinese hamster ovary (CHO) cells TebentafuspKIMMTRAKgp100, CD3scFv-TCR fusion proteinBispecificHumanizedscFv fused with a TCRTo be confirmedImmunoconjugateNone-CancerMetastatic uveal melanoma20222022US, 2022E. coli bacteria TeclistamabTECVAYLIBCMA, CD3Full-length antibodyBispecificHumanizedIgG4; Hetero H, HL exchangedlambdaUnconjugatedHetero HH: F405L-R409K x WT (R409); both chains: S228P and F234A, L235AHinge-stabilising (S228P) and Fc-silencing (F234A, L235A)CancerMultiple myeloma20222022EU, 2022Chinese hamster ovary (CHO) cells TeplizumabTZIELDCD3Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedL234A; L235AReduce Fc effector functionsImmune-mediated disordersType 1 diabetesEU review2022US, 2022Chinese hamster ovary (CHO) cells Teprotumumab (teprotumumab-trbw)TepezzaIGF-1RFull-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-OphthalmologyThyroid eye diseaseEU review2020US, 2020Chinese hamster ovary (CHO) cells TezepelumabTezspireThymic stromal lymphopoietinFull-length antibodyMonospecificHumanIgG2lambdaUnconjugatedNone-Immune-mediated disordersSevere asthma20222021US, 2021Chinese hamster ovary (CHO) cells Tildrakizumab (tildrakizumab-asmn)IlumyaIL-23 p19Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-Immune-mediated disordersPlaque psoriasis20182018US, 2018Chinese hamster ovary (CHO) cells TislelizumabTevimbraPD-1Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228P; E233P, F234V, L235A, D265AHinge stabilising; Abrogate FcγRs bindingCancerEsophageal squamous cell carcinoma20232024China, 2019Chinese hamster ovary (CHO) cells Tisotumab vedotin, tisotumab vedotin-tftvTIVDAKTissue factorFull-length antibodyMonospecificHumanIgG1kappaADCCleable mc-val-cit-PABC type linkerMonomethyl Auristatin E (MMAE)tubulin polymerization inhibitorNone-CancerCervical cancerEU review2021US, 2021Chinese hamster ovary (CHO) cells Tixagevimab, cilgimabEvusheldSARS-CoV-2Full-length antibodies, mixture of 2Mixture of 2 monospecific antibodiesHumanIgG1kappaUnconjugatedL234F L235E M252Y S254T T256E P331SReduce Fc effector function (L234F L235E P331S) and extend half-life ( M252Y S254T T256E)Infectious diseasesCOVID-192022EUA#EU, 2022Chinese hamster ovary (CHO) cells TocilizumabRoActemra, ActemraIL-6RFull-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-Immune-mediated disordersRheumatoid arthritis20092010Japan, 2005Chinese hamster ovary (CHO) cells ToripalimabLOQTORZI, TuoyiPD-1Full-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge stabilisingCancerNasopharyngeal carcinoma20242023China, 2018Chinese hamster ovary (CHO) cells Tositumomab-I131BexxarCD20Full-length antibodyMonospecificMurinemIgG2alambdaRICIodine-131I-131 produces beta and gamma emissionsNone-CancerNon-Hodgkin LymphomaNA2003#US, 2003Murine hybridoma TralokinumabAdtralzaIL-13Full-length antibodyMonospecificHumanIgG4lambdaUnconjugatedNone-Immune-mediated disordersAtopic dermatitis20212021EU, 2021Mouse myeloma cells TrastuzumabHerceptinHER2Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-CancerBreast cancer20001998US, 1998Chinese hamster ovary (CHO) cells TremelimumabImjudoCTLA-4Full-length antibodyMonospecificHumanIgG2kappaUnconjugatedNone-CancerAntineoplastic; liver cancer20232022US, 2022Murine myeloma non-secreting 0 (NS0) cells UblituximabBRIUMVICD20Full-length antibodyMonospecificChimeric mouse/humanIgG1kappaUnconjugatedLow fucoseImprove FcγRIIIa binding/Improve ADCCImmune-mediated disordersMultiple sclerosis20232022US, 2022YB2/0 cells UstekinumabStelaraIL-12/23Full-length antibodyMonospecificHumanIgG1kappaUnconjugatedNone-Immune-mediated disordersPsoriasis20092009EU, 2009Murine myeloma cells (Sp2/0) VedolizumabEntyvioα4β7 integrinFull-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedL235A, G237Reduce Fc effector functionsImmune-mediated disordersUlcerative colitis, Crohn disease20142014US, 2014Chinese hamster ovary (CHO) cells ZimberelimabYuTuo®PD-1Full-length antibodyMonospecificHumanIgG4lambdaUnconjugatedS228PHinge stabilisationCancerClassical Hodgkin’s lymphomaNANAChina, 2021To be confirmed ZolbetuximabVYLOYClaudin-18.2Full-length antibodyMonospecificChimeric mouse/humanIgG1kappaUnconjugatedNoneCancerHER2-negative gastric or gastroesophageal junction adenocarcinoma20242024Japan, 2024Chinese hamster ovary (CHO) cells ZuberitamabEnrexibCD20Full-length antibodyMonospecificChimeric mouse/humanIgG1kappaUnconjugatedNoneCancerCD20-positive diffuse large B-cell lymphomaNANAChina, 2023To be confirmed OdronextamabOrdsponoCD20, CD3Full-length antibodyBispecificHumanIgG4 Hetero H, cLkappaUnconjugatedHetero HH: WT x H435R-Y436F; HL-pairing: cL ; both chains: E233P, F234V, L235A, G236del; S228P Hetero HH: WT x H435R-Y436F (limits binding of the anti-CD3 Fc to Protein A, purification); HL-pairing: cL ; both chains: E233P, F234V, L235A, G236del (Fc-silencing), S228P (hinge-stabilization)CancerRelapsed/refractory (R/R) follicular lymphoma or R/R diffuse large B-cell lymphoma 2024In reviewEU, 2024Chinese hamster ovary (CHO) cells Recaticimab(Pending)PCSK9Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedM252Y, S254T, T256EExtends half-lifeMetabolic disordersHypercholesterolemiaNANARegulatory review in ChinaTo be confirmed Vunakizumab(Pending)IL-17AFull-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNoneImmune-mediated disordersPsoriasisNANAChina, 2024To be confirmed Ivonescimab依達方®PD-1, VEGFFull-length IgG1 kappa - [scFv]2BispecificIgG1kappaUnconjugatedL234A, L235AReduce Fc effector functionsCancerNon-small cell lung cancerNANAChina, 2024To be confirmed Ebdarokimab(Pending)IL-12/23p40Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNoneImmune-mediated disordersPsoriasisNANARegulatory review in ChinaTo be confirmed BenmelstobartAndeweiPD-L1Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedD265AReduce Fc effector functionsCancerSmall cell lung cancerNANAChina, 2024To be confirmed VilobelimabGohibicComplement C5aFull-length antibodyMonospecificChimeric mouse/humanIgG4kappaUnconjugatedNoneHemostasisSARS-CoV-2 induced septic acute respiratory distress syndrome2025NAEU, 2025To be confirmed Suciraslimab(Pending)CD22Full-length antibodyMonospecificChimeric mouse/humanIgG1kappaUnconjugatedNoneImmune-mediated disordersRheumatoid arthritisNANARegulatory review in ChinaTo be confirmed Trastuzumab botidotin(Pending)HER2Full-length antibodyMonospecificHumanizedIgG1kappaADCCleable valine-citrulline linkerDuostatin-5Tubulin inhibitorNoneCancerBreast cancerNANARegulatory review in ChinaTo be confirmed Iparomlimab(Pending)PD-1Full-length antibodyMonospecificHumanized/chimericIgG4kappaUnconjugatedS228PHinge stabilisationCancerCervical cancerNANARegulatory review in ChinaTo be confirmed Iparomlimab, tuvonralimab齐倍安®PD-1, CTLA-4Full-length antibodyMixture of 2 monospecific antibodiesHumanized/chimeric, humanizedIgG4 (anti-PD-1); IgG1 (anti-CTLA4)kappaUnconjugatedIgG4: S228P; IgG1: K147D, F170C, V173C, C220G, R255K, D399R, K409E on the hey chain, and S131K, Q160C, S162C, C214S on the light chainHinge stabilisation; hey and light chain pairingCancerCervical cancerNANAChina, 2024To be confirmed Xeligekimab金立希IL-17AFull-length antibodyMonospecificHumanIgG4kappaUnconjugatedS228PHinge stabilisationImmune-mediated disordersPlaque PsoriasisNANAChina, 2024To be confirmed MarstacimabHympziTissue factor pathway inhibitorFull-length antibodyMonospecificHumanIgG1lambdaUnconjugatedL234A, L235A, G237AReduce Fc effector functionsCardiovascular / hemostasisHemophilia20242024US, 2024Chinese hamster ovary (CHO) cells GaradacimabAndembryFactor XIIaFull-length antibodyMonospecificHumanIgG4lambdaUnconjugatedS228PHinge stabilisationCardiovascular / hemostasisPrevention of hereditary angioedema attacks2025In reviewAustralia, 2025To be confirmed StapokibartKangyueda, 康悦达IL-4R alphaFull-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge stabilisationImmune-mediated disorders Atopic dermatitisNANAChina, 2024To be confirmed TarlatamabIMDELLTRADLL3, CD3scFv-scFv-scFcBispecificUnconjugatedR292C, N297G, V302CAglycosylation, CH2 stabilization (in the absence of glycosylation)CancerSmall cell lung cancerNA2024US, 2024Chinese hamster ovary (CHO) cells Patritumab deruxtecan (Pending)HER3Full-length antibodyMonospecificHumanIgG1kappaADCGGFG; Cleable linkerDXd/DX-8951Topoisomerase I inhibitorNoneCancerNon-small cell lung cancerNAIn reviewTo be confirmed Sacituzumab tirumotecan 佳 泰 萊®TROP-2Full-length antibodyMonospecificHumanizedIgG1kappaADCStable linkerTopoisomerase I inhibitorNoneCancerBreast cancerNANAChina, 2024To be confirmed Axatilimab, axatilimab-csfrNiktimvoCSF-1RFull-length antibodyMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge stabilisationImmune-mediated disorders Graft vs. host diseaseNA2024US, 2024Chinese hamster ovary (CHO) cells Zanidatamab, zanidatamab-hriiZiihera®HER2, HER2 (biparatopic)scFv-Fc x Fab-Fc BispecificHumanizedUnconjugatedT350V-L351Y-F405A-Y407V x T350V-T366L-K392L-T394WHetero HHCancerBiliary tract cancers EU review2024US, 2024Chinese hamster ovary (CHO) cells LinvoseltamabLynozyficBCMA, CD3Full-length antibodyBispecificHumanIgG4kappaUnconjugatedS228P; Hetero H, cL. Hetero HH: WT x H435R-Y436F; both chains: E233P, F234V, L235A, G236delHinge stabilization; Limits binding to Protein A, purification; Fc-silencingCancerMultiple myelomaPos. opinion after reviewIn reviewTo be confirmed Datopotamab deruxtecanDATROWAY®TROP-2Full-length antibodyMonospecificHumanizedIgG1kappaADCGlycine-Glycine-Phenylalanine-Glycine; Tetrapeptide-based cleable linkerDXd/DX-8951Topoisomerase I inhibitorNoneCancerBreast cancer (HR+, HER2-)Pos. opinion after review2025Japan, 2024Chinese hamster ovary (CHO) cells Zenocutuzumab, zenocutuzumab-zbco BIZENGRI®HER2, HER3Full-length antibodyBispecificHumanizedIgG1kappaUnconjugatedL351K, T366KHeterodimerization CancerNeuregulin 1 fusion (NRG1+) non-small cell lung (NSCLC) and NRG1+ pancreatic (PDAC) cancerNA2024US, 2024Chinese hamster ovary (CHO) cells NurulimabNurdatiCTLA-4Full-length antibodyMonospecificHumanIgG1kappaUnconjugatedCancerMelanomaNANARussia, 2023To be confirmed SeniprutugTribuviaTCR Vbeta9Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedNone-Immune-mediated disorders Axial SpondyloarthritisNANARussia, 2024To be confirmed Suvemcitug(Pending)VEGFFull-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedCancerRecurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancerNANARegulatory review in ChinaTo be confirmed No INN; Genakumab(Pending)IL-1betaFull-length antibodyMonospecificUnconjugatedImmune-mediated disorders Acute gouty arthritisNANARegulatory review in ChinaTo be confirmed Siltartoxatug新替妥Tetanus toxinFull-length antibodyMonospecificHumanUnconjugatedInfectious diseaseTetanusNANAChina, 2025To be confirmed Teprotumumab N01SYCUME®IGF-1RFull-length antibodyMonospecificHumanIgG1kappaUnconjugatedImmune-mediated disorders Thyroid Eye DiseaseNANAChina, 2025To be confirmed Bifikafusp alfa, Onfekafusp alfaNidlegy™Fibronectin extra-domain BscFv fused with IL-2, scFv fused with TNFMixture of 2 monospecific antibodiesHumankappaImmunocytokineIL-2, TNFCancerMelanomaEU reviewNATo be confirmed Bentracimab(Pending)TicagrelorFabMonospecificHumanlambdaUnconjugatedNA-Cardiovascular / hemostasisReversal of the antiplatelet effects of ticagrelorNAIn reviewTo be confirmed Nipocalimab(Pending)FcRnFull-length antibodyMonospecificHumanIgG1lambdaUnconjugatedN297AFc-aglycosylatedImmune-mediated disorders Generalized myasthenia grisEU reviewIn reviewTo be confirmed Mazorelvimab, Zamerovimab克瑞毕®Rabies virus glycoproteinFull-length antibodyMixture of 2 monospecific antibodiesHumanizedIgG1kappaUnconjugatedNoneInfectious diseaseRabies preventionNANAChina, 2024To be confirmed Picankibart(Pending)IL-23p19Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedM252Y, S254T, T256E Extends half-lifeImmune-mediated disorders PsoriasisNANARegulatory review in ChinaTo be confirmed Telisotuzumab vedotin(Pending)cMETFull-length antibodyMonospecificHumanizedIgG1kappaADCValine–citrulline (Cleable linker)MMAEK222C T223del T225del K447delCancerNonsquamous non-small cell lung cancerNAIn reviewTo be confirmed Finotonlimab(Pending)PD-1Full length AbMonospecificHumanizedIgG4kappaUnconjugatedS228PHinge stabilizationCancerHead and neck cancer; Hepatocellular carcinoma NANAChina, 2025To be confirmed Retlirafusp alfa(Pending)PD-L1, TGF betaFull length Ab fusionBispecificHumanIgG4kappaImmunoconjugateTGFbeta receptor II ECDS228PHinge stabilizationCancerGastric and gastroesophageal junction adenocarcinomaNANARegulatory review in ChinaTo be confirmed Becotatug vedotin(Pending)EGFRFull-length antibodyMonospecificHumanizedIgG1kappaADCValine–citrulline (Cleable linker)MMAENone foundCancerHead and neck cancerNANARegulatory review in ChinaTo be confirmed No INN; SSGJ-608, 608(Pending)IL-17AFull-length antibodyMonospecificTBDTBDTBDUnconjugatedTBDImmune-mediated disorders PsoriasisNANARegulatory review in ChinaTo be confirmed Clesrovimab(Pending)RSV (F glycoprotein)Full-length antibodyMonospecificHumanIgG1kappaUnconjugatedM252Y, S254T, T256E Extends half-lifeInfectious diseasePrevention of RSV infectionEU reviewReviewTo be confirmed SipibartKigaleSARS-CoV-2Full-length antibodyMonospecificHumanIgG1lambdaUnconjugatedL234F, L235E, P331S; M252Y, S254T, T256EReduced effector function; extends half-lifeInfectious diseasePrevention of COVIDPos. opinion after reviewNATo be confirmed Depemokimab(Pending)IL-5Full-length antibodyMonospecificHumanizedIgG1kappaUnconjugatedM252Y, S254T, T256EExtends half-lifeImmune-mediated disorders Asthma, chronic rhinosinusitis with nasal polypsEU reviewNARegulatory review in China, JapanTo be confirmed Apitegromab(Pending)MyostatinFull-length antibodyMonospecificHumanIgG4lambdaUnconjugatedS228PHinge stabilizationMuscular disordersSpinal muscular atrophy NAIn reviewTo be confirmed Gumokimab(Pending)IL-17AFull-length antibodyMonospecificTBDIgG1kappaUnconjugatedNone foundImmune-mediated disorders Plaque psoriasisNANARegulatory review in ChinaTo be confirmed No INN; ALXN2220(Pending)Amyloid transthyretinFull-length antibodyMonospecificHumanIgG1UnconjugatedCardiovascular / hemostasis disordersTransthyretin amyloid cardiomyopathyNANARegulatory review in JapanTo be confirmedTable notes: *, Country-specific approval. #, Withdrawn or marketing discontinued. NA, not approved or in review in the EU; not approved or information on review status not ailable in US.
In the backbone column, the isotype refers to human unless indicated otherwise with the prefix m- (murine) or r- (rat).
Sequence and structure information can be accessed on the IMGT/mAb-DB website.
Antibody therapeutics that are approved for marketing in regions other than the EU or US include: Nimotuzumab (TheraCIM®, BIOMAB-EGFR®), humanized anti-EGFR IgG1 approved in numerous countries for various forms of solid tumors starting in the 2000s.
Itolizumab (Alzumab), humanized anti-CD6 IgG1 approved in India in January 2013 for psoriasis; Rmab (RabiShield), human anti-rabies virus G glycoprotein IgG1 approved in India in 2016 for post-exposure prophylaxis of rabies; RabiMabs (Twinrab TM), mixture of 2 anti-rabies virus mAbs approved in India in 2019.
Sintilimab (Tyvyt), human IgG4 anti-PD-1 mAb approved in China in December 2018 for Hodgkin’s lymphoma; Toripalimab (Tuoyi), humanized anti-PD-1 mAb approved in China in December 2018 for melanoma; Camrelizumab, humanized anti-PD-1 mAb approved in China in 2019 for Hodgkin’s lymphoma; Tislelizumab, humanized anti-PD-1 mAb, approved in China in December 2019 as a treatment for classical Hodgkin’s lymphoma; Disitamab vedotin (Aidixi), anti-HER2 humanized ADC approved in China in June 2021 as a treatment for gastric cancer; Penpulimab, ant-PD-1 humanized mAb approved in China in August 2021 for Hodgkin’s lymphoma; Zimberelimab, anti-PD-1 human mAb approved in China in August 2021 for Hodgkin’s lymphoma.
Netakimab (Efleira), anti-IL-17 mAb approved in Russia in 2019 for plaque psoriasis; Prolgolimab (Forteca), anti-PD-1 mAb approved in Russia in 2020 for melanoma; Olokizumab (Artlegia), anti-IL-6 humanized IgG4 approved in Russia in 2020 for rheumatoid arthritis; Levilimab (Ilsira) anti-IL-6R human mAb approved in Russia in 2020 for COVID-19.
Cetuximab saratolacan sodium, anti-EGFR mAb approved in Japan in September 2020 for head and neck cancer; Pabinafusp alfa (IZCARO), anti-transferrin receptor inmmunoconjuate approve in Japan in March 2021 for Hunter syndrome.
Sotrovimab, anti-SARS-CoV-2 antibody approved in Australia in August 2021. Regdanvimab, anti-SARS-CoV-2 antibody approved in the Republic of Korea in September 2021.